http://www.newscientist.com/article/dn8956I wonder if there's any difference between official interim report and just report. Anyway, the explanation is out.
According to it, the severe patient reaction in the first human phase I safety trial of the drug was not due to a dosing error, product contamination or manufacturing problems, and the trial was conducted properly according to the agreed protocol, the Medicines and Healthcare products Regulatory Agency (MHRA).
The drug administered to them are much more lower, and shouldn't have caused problems, according to experts. The UK government is investigating.